Impacts of 18F-FDG PET/CT Parameters on Differential Diagnosis and Outcome of Patients with Primary Invasive Mucinous and Lepidic Predominant Adenocarcinoma of the Lung.

IF 0.9 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Ebru Tatcı, Özlem Özmen, Derya Kızılgöz, Funda Demirağ, Seçkin Bilgiç
{"title":"Impacts of <sup>18</sup>F-FDG PET/CT Parameters on Differential Diagnosis and Outcome of Patients with Primary Invasive Mucinous and Lepidic Predominant Adenocarcinoma of the Lung.","authors":"Ebru Tatcı, Özlem Özmen, Derya Kızılgöz, Funda Demirağ, Seçkin Bilgiç","doi":"10.4274/mirt.galenos.2024.24571","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>The purpose of this study was to investigate whether <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) parameters have a role in differentiating invasive mucinous lung adenocarcinoma (IMA) from lepidic predominant lung adenocarcinoma (LPA). Additionally, we compared the <sup>18</sup>F-FDG-PET/CT features between survivors and non-survivors.</p><p><strong>Methods: </strong>Tumors were divided into 2 groups according to CT appearance: Group 1: nodular-type tumor; group 2: mass- or pneumonic-type tumor. Unilateral and bilateral multifocal diseases were detected. Clinicopathological characteristics and PET/CT findings were compared between IMAs and LPAs, as well as between survivors and non-survivors.</p><p><strong>Results: </strong>We included 43 patients with IMA and 14 with LPA. Tumor size (p=0.003), incidence of mass/pneumonic type (p=0.011), and bilateral lung involvement (p=0.049) were higher in IMAs than in LPAs. IMAs had more advanced T, M, and Tumor, Node, and Metastasis stages than in LPAs (p=0.048, p=0.049, and p=0.022, respectively). There was no statistically significant difference in maximum standardized uptake value (SUV<sub>max</sub>) between the IMA and LPA (p=0.078). The SUV was significantly lower in the nodular group than in the mass/pneumonic-type group (p=0.0001). A total of 11 patients died, of whom SUV<sub>max</sub> values were significantly higher in these patients (p=0.031). Male gender (p=0.0001), rate of stage III-IV (p=0.0001), T3-T4 (p=0.021), M1 stages (p=0.0001), multifocality (p=0.0001), and bilateral lung involvement (p=0.0001) were higher in non-survivor.</p><p><strong>Conclusions: </strong>Although CT images were useful for the differential diagnosis of LPAs and IMAs, SUV<sub>max</sub> was not helpful for differentiation of these 2 groups. However, both <sup>18</sup>F-FDG uptake and CT findings may play an important role in predicting prognosis in these patients.</p>","PeriodicalId":44681,"journal":{"name":"Molecular Imaging and Radionuclide Therapy","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging and Radionuclide Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4274/mirt.galenos.2024.24571","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: The purpose of this study was to investigate whether 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) parameters have a role in differentiating invasive mucinous lung adenocarcinoma (IMA) from lepidic predominant lung adenocarcinoma (LPA). Additionally, we compared the 18F-FDG-PET/CT features between survivors and non-survivors.

Methods: Tumors were divided into 2 groups according to CT appearance: Group 1: nodular-type tumor; group 2: mass- or pneumonic-type tumor. Unilateral and bilateral multifocal diseases were detected. Clinicopathological characteristics and PET/CT findings were compared between IMAs and LPAs, as well as between survivors and non-survivors.

Results: We included 43 patients with IMA and 14 with LPA. Tumor size (p=0.003), incidence of mass/pneumonic type (p=0.011), and bilateral lung involvement (p=0.049) were higher in IMAs than in LPAs. IMAs had more advanced T, M, and Tumor, Node, and Metastasis stages than in LPAs (p=0.048, p=0.049, and p=0.022, respectively). There was no statistically significant difference in maximum standardized uptake value (SUVmax) between the IMA and LPA (p=0.078). The SUV was significantly lower in the nodular group than in the mass/pneumonic-type group (p=0.0001). A total of 11 patients died, of whom SUVmax values were significantly higher in these patients (p=0.031). Male gender (p=0.0001), rate of stage III-IV (p=0.0001), T3-T4 (p=0.021), M1 stages (p=0.0001), multifocality (p=0.0001), and bilateral lung involvement (p=0.0001) were higher in non-survivor.

Conclusions: Although CT images were useful for the differential diagnosis of LPAs and IMAs, SUVmax was not helpful for differentiation of these 2 groups. However, both 18F-FDG uptake and CT findings may play an important role in predicting prognosis in these patients.

18F-FDG PET/CT 参数对原发性侵袭性黏液腺癌和以表皮为主的肺腺癌患者的鉴别诊断和预后的影响
研究目的本研究旨在探讨18F-氟脱氧葡萄糖(18F-FDG)正电子发射断层扫描/计算机断层扫描(PET/CT)参数是否有助于区分浸润性粘液性肺腺癌(IMA)和鳞状上皮型肺腺癌(LPA)。此外,我们还比较了存活者和非存活者的 18F-FDG-PET/CT 特征:方法:根据CT表现将肿瘤分为两组:第一组:结节型肿瘤;第二组:肿块型或气肿型肿瘤。检测单侧和双侧多灶性疾病。比较了 IMA 和 LPA 以及存活者和非存活者的临床病理特征和 PET/CT 结果:结果:我们纳入了 43 名 IMA 患者和 14 名 LPA 患者。IMA患者的肿瘤大小(p=0.003)、肿块/肺型的发生率(p=0.011)和双肺受累(p=0.049)均高于LPA患者。与LPA相比,IMA的T期、M期、肿瘤期、结节期和转移期更为晚期(分别为p=0.048、p=0.049和p=0.022)。IMA和LPA的最大标准化摄取值(SUVmax)差异无统计学意义(P=0.078)。结节组的 SUV 值明显低于肿块/气肿型组(P=0.0001)。共有 11 名患者死亡,其中这些患者的 SUVmax 值明显更高(P=0.031)。男性(p=0.0001)、III-IV期(p=0.0001)、T3-T4期(p=0.021)、M1期(p=0.0001)、多发(p=0.0001)和双肺受累(p=0.0001)在非存活患者中的比例较高:结论:虽然CT图像有助于鉴别诊断LPA和IMA,但SUVmax并不能帮助区分这两类患者。然而,18F-FDG 摄取和CT结果可能在预测这些患者的预后方面发挥重要作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Imaging and Radionuclide Therapy
Molecular Imaging and Radionuclide Therapy RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING-
CiteScore
1.30
自引率
0.00%
发文量
50
期刊介绍: Molecular Imaging and Radionuclide Therapy (Mol Imaging Radionucl Ther, MIRT) is publishes original research articles, invited reviews, editorials, short communications, letters, consensus statements, guidelines and case reports with a literature review on the topic, in the field of molecular imaging, multimodality imaging, nuclear medicine, radionuclide therapy, radiopharmacy, medical physics, dosimetry and radiobiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信